ArticleFrontiers in robotics and AI2024
Launching Stealth AutoGuide
Article in Frontiers in robotics and AI, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stereotactic robotic transcerebellar-transpeduncular pontomedullary biopsy: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Early Clinical Experience with the Stealth Autoguide Cranial Robotic Guidance Platform for Stereotactic Brain Biopsy.Journal of Korean Neurosurgical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate histological analysis is crucial for confirming intracerebral neoplasia due to the diverse array of potential diagnoses presented by imaging. In the realm of biopsy techniques, the use of robot-based systems is on the rise, primarily owing to their heightened targeting accuracy. The objective of this study was to elucidate the practicality, learning curve and workflow associated with robot-guided biopsies upon their introduction to a neurosurgical centre. Materials and methods: In March 2022, the neurosurgical department at our institution adopted the Medtronic Stealth AutoGuide™ cranial robotic guidance platform, a miniaturized robotic guidance device designed for stereotactic procedures. Four experienced neurosurgeons underwent training with the Stealth AutoGuide™ system, after which 51 consecutive biopsies were performed. The evaluation encompassed entry and target accuracy, preoperative setup time, time required for the biopsy procedure, and overall operating time. Statistical analysis was conducted to identify any differences between the initial 26 and subsequent sets of 25 patients, with the aim of identifying changes in workflow. Results: The study included all patients necessitating a diagnostic biopsy for intracerebral tumours, with only one patient excluded due to the inaccessibility of the intended target point caused by tumour calcification. Notably, there were no significant differences between the first 25 and last 26 patients in the median time from incision to the first biopsy (overall: 11.5 min, IQR 9.03-15.0), the procedure time (overall: 30.0 min, IQR 23.5-46.5), median accuracy at entry (overall: 2.05 mm, IQR 0.8-3.8), or target point (overall: 2.2 mm (IQR 1.6-3.7). However, a significant reduction in robot setup time was observed between the two groups, median 2.69 min versus 1.17 min, respectively (p ≤ 0.001). Conclusion: The deployment of the robotic biopsy system, Stealth AutoGuide™, showed high feasibility, steep learning curve due to uncomplicated technical handling using our standardized operative workflow. Therefore, even in prone position a high diagnostic yield was achieved. Overall, the Stealth AutoGuide™ system facilitated biopsies in traditionally challenging regions with concise procedure time and surgeon-independent high accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.